Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Pyrotinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Pyrotinib is a once-daily targeted tablet for HER2-positive breast cancer. It was discovered and is made in China by Jiangsu Hengrui Pharmaceuticals, and it is sold there under the brand name 艾瑞妮® (Irene®).
Its first Chinese licence, for use with capecitabine, came as a conditional NMPA approval in August 2018 and became a full approval in July 2020. Two more breast cancer uses have been added since, so the approved list in China now reads:
This is a prescription cancer medicine and should only be started and monitored by a medical oncologist.
In HER2-positive breast cancer, the cancer cells carry too many HER2 receptors, which keep sending "grow and divide" signals. This medicine is a small molecule that slips inside the cell and binds permanently (irreversibly) to the switch area of three related receptors: HER1 (EGFR), HER2 and HER4. Because it acts from inside the cell, it can still block the signal when antibody treatments given as drips have stopped working well.
The approval with capecitabine rests on the phase 3 PHOEBE study (The Lancet Oncology, 2021). It enrolled 267 women whose metastatic breast cancer had been treated before with a HER2 antibody and a taxane. With the capecitabine combination, the cancer was held in check for a median of 12.5 months, against 6.8 months with a comparison medicine plus capecitabine.
In the first-line PHILA trial (BMJ, 2023; 590 patients), adding it to standard HER2 treatment lengthened median progression-free survival from 10.4 to 24.3 months. Before surgery, the PHEDRA trial (BMC Medicine, 2022; 355 patients) found no remaining invasive cancer in the breast and lymph nodes in 41.0% of people, compared with 22.0% on placebo.
In the trials, the usual dose was:
The tablets come in 80 mg and 160 mg strengths, so the daily dose is made up from a mix of the two. Follow the exact plan your oncologist and the Chinese pack leaflet give you.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Diarrhoea: this is the side effect that matters most. Severe (grade 3 or worse) diarrhoea affected 31% of patients in PHOEBE, 44.4% in PHEDRA and 46% in PHILA. It tends to be worst in the first three-week cycle and usually eases after that. Keep anti-diarrhoea tablets at home as your doctor advises, drink plenty of fluids, and call the team if loose stools do not settle within a day.
Other points: serious side effects were reported in 10% of PHOEBE patients. Tell your doctor about every other medicine and supplement you take, and use reliable contraception, because safety in pregnancy and breastfeeding has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
A named-patient import is allowed only in the patient's own name, under Indian rules for unapproved medicines. Please keep these ready:
We confirm an order only after the prescription has been checked and, where it applies, the import permit has been issued.
No. It is not approved by CDSCO and is not stocked in Indian chemists. CDSCO's expert committee has allowed a phase 3 study in India, but a trial permission is not a marketing licence. It is also not approved by the US FDA, and we found no European approval.
A treating doctor can still request it for one named patient through the Named Patient Program. Another oral HER2 tablet we arrange on the same import basis is Nerlynx.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The tablets are stored and shipped as directed on the Chinese pack, in sealed original packaging. Since treatment is taken daily for months, we can plan supply in monthly lots so there is no gap between packs. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can receive this oral HER2 medicine through a regulated import route, delivered to their home or treating hospital against a valid oncologist's prescription.
Breast cancer clinics in the capital can send the prescription and HER2 report to our New Delhi team, which handles dispatch locally.
Supplies reach oncology departments and patients' homes across Mumbai once the import papers are cleared.
Oncologists here can request the tablets for a named patient and see the written quote before ordering.
Patients being treated at Chennai's large cancer hospitals can receive monthly packs without a break in therapy.
We match the delivery date to the start of each capecitabine cycle so both medicines are on hand together.
Families in Kolkata and the north-east are kept informed at each step, from permit to doorstep.
Women on long-term oral treatment in Pune can arrange repeat supply from one prescription renewal to the next.
The oncologist only needs to share the prescription, pathology report and treatment summary for us to begin.
Patients under care at Vellore's teaching hospitals can have each lot delivered to the hospital pharmacy.
Covers patients travelling from Punjab, Haryana, Himachal and Jammu for breast cancer care.
We coordinate delivery to cancer centres across Uttar Pradesh, both government and private.
Patients across Kerala can collect the medicine in Kochi or have it sent to their treating hospital.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 18 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message